Click here to close now.

SYS-CON MEDIA Authors: Aria Blog, Pat Romanski, Elizabeth White, Peter Silva, Glenn Rossman

News Feed Item

Echo Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Provides Business Update

40%-50% Monthly Cash Burn Reduction Initiatives Implemented

PHILADELPHIA, Aug. 14, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced its financial results for the quarter ended June 30, 2014 and provided a business update.  Echo's Quarterly Report on Form 10-Q, as filed with the SEC, is available by visiting the Investors section of Echo's website at www.echotx.com.

Echo also announced today that it has taken steps to substantially reduce operating costs and preserve cash while further focusing its development efforts and resources on implementing key product performance enhancements to its Symphony CGM System. The Company has implemented significant cost reductions across all aspects of its operations in both external spend and workforce, including reductions in general and administrative expenditures, manufacturing, clinical and product development expenditures. At the same time, the Company is exploring a variety of funding alternatives which it believes, together with the cost reduction initiatives, is necessary to permit the Company to ultimately achieve its clinical trial and regulatory approval objectives. In the absence of a financing or strategic transaction, Echo's ability to achieve its previously stated product development timelines will be negatively impacted by the Company's effort to preserve cash and reduce expenses.

Cost reduction measures that were successfully implemented in September 2013 resulted in a 36% decrease in second quarter of 2014 operating expenses compared to the second quarter of 2013. The Company anticipates an additional meaningful decrease in expenses as a result of the most recent cost reduction efforts. As a result of these new initiatives, that include a 35% employee reduction, the monthly burn rate is projected to decrease by 40%-50% as compared to the average monthly burn rate experienced during the first six months of 2014.

"Our management team and Board of Directors believe more than ever in the viability of Symphony and in the positive product development progress made in the past few months; however, it is in the best interests of Echo and its shareholders to take immediate and significant action to adjust our business and operating structure in order to achieve cost savings, preserve cash and deploy capital more efficiently as we continue to make progress toward commercialization. Our focus continues to be prudent with our spending while implementing and testing the key product enhancements for the next generation Symphony CGM System," said Kimberly A. Burke, Echo's Interim CEO, General Counsel and Chief Compliance Officer. "We remain excited about the potential for Symphony as an important tool to improve glycemic control in the critical care setting and we believe that additional market segment and partnership opportunities exist for various demographics. Our SkinPrep technology also offers multi-product opportunities for use as a drug delivery device or in combination with other biosensors to monitor additional analytes."

Other Recent Corporate Updates:

  • In June 2014, Echo's clinical study of Symphony was presented during poster sessions at the 74th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California.
  • Stockholders elected Shepard M. Goldberg to the Echo Board of Directors at the 2014 Annual Meeting of Stockholders held on June 19, 2014.
  • Kimberly A. Burke was appointed as Interim Chief Executive Officer (CEO) of Echo effective July 1, 2014. The Board continues to work with a retained executive search firm to hire a well-qualified permanent CEO.
  • Charles T. Bernhardt was appointed by the Echo Board of Directors to serve as Interim Chief Financial Officer (CFO) on July 16, 2014.

Second Quarter 2014 Financial Results

Echo's net loss for the second quarter of 2014 was $3.8 million, or ($0.31) per share, compared to $3.3 million, or ($0.51) per share, for the second quarter of 2013.  Operating loss for the second quarter of 2014 was $3.9 million compared to $6.1 million for the second quarter of 2013.  Research and development expenses were $1.7 million for the second quarter of 2014 compared to $4.0 million in the prior year.  The decrease in research and development expenses is primarily related to decreased development and clinical expenses.  General and administrative expenses were $2.2 million for the second quarter of 2014 versus $2.1 million in the prior year.  A decrease in general and administrative expenses was offset by unanticipated expenses that included costs associated with the proxy contest and annual shareholder meeting and legal expenses.  Echo reported a cash balance of approximately $4.1 million as of June 30, 2014.  

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system for use initially in the critical care setting. A significant longer-term opportunity may also exist for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting. Echo has also developed its needle-free skin preparation device as a platform technology to allow for enhanced skin permeation that enables extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts, including the statements about future decreases in expense, corporate objectives, a European product launch and initiation of the FDA pivotal trial, may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's clinical studies, the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2013, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio   
Director, Investor Relations and Corporate Communications
(215) 717-4104                      

Connect With Us:
- Visit our website at www.echotx.com 
- Follow us on Twitter at www.twitter.com/echotx 
- Join us on Facebook at www.facebook.com/echotx


 

Echo Therapeutics, Inc

Condensed Consolidated Balance Sheets

(Unaudited)



  June 30,

2014


December 31,

2013


ASSETS





Current Assets:





Cash and cash equivalents

$      4,105,954


$      8,055,385


Other current assets

1,228,991


1,319,713


Total current assets

5,334,945


9,375,098


Net property and equipment (including assets under capitalized leases)

1,329,539


1,495,807


Other Assets:





Intangible assets, net of accumulated amortization

9,625,000


9,625,000


Deferred financing costs, net of current portion

2,097,322


2,581,324


Restricted cash and other assets

11,490


12,066


Total other assets

11,733,812


12,218,390


Total assets

$    18,398,296


$    23,089,295







LIABILITIES AND STOCKHOLDERS' EQUITY





Current Liabilities:





Accounts payable

$      1,032,360


$      1,036,320


Current portion of deferred revenue from licensing agreements

76,428


76,428


Derivative warrant liability

586,155


1,119,155


Accrued expenses and other liabilities

884,201


1,412,468


Total current liabilities

2,579,144


3,644,371


Deferred revenue from licensing arrangements, net of current portion

38,214


76,428


Total liabilities

2,617,358


3,720,799


Commitments and contingencies





Stockholders' Equity:





Convertible preferred stock, Series C, D & E

27,496


27,496


Common stock

126,654


117,764


Additional paid-in capital

135,133,217


132,192,648


Accumulated deficit

(119,506,429)


(112,969,412)


Total stockholders' equity

15,780,938


19,368,496


Total liabilities and stockholders' equity

$    18,398,296


$    23,089,295


 

 

Condensed Consolidated Statements of Operations

(Unaudited)


Three Months Ended

June 30,


Six Months Ended

June 30,


2014


2013


2014


2013

Licensing revenue

$ 19,107


$ 22,557


$ 38,214


$ 45,114

Total revenues

19,107


22,557


38,214


45,114









Operating Expenses:








Research and development

1,747,254


4,019,149


3,148,162


7,238,872

Selling, general and administrative

2,187,335


2,098,347


3,475,235


4,397,794

Total operating expenses

3,934,589


6,117,496


6,623,397


11,636,666

Loss from operations

(3,915,482)


(6,094,939)


(6,585,183)


(11,591,552)









Other Income (expense):








Interest income (expense), net

(242,994)


(241,458)


(486,334)


(3,414,156)

Gain on disposals of assets

1500


-


1500


-

Gain on revaluation of derivative warrant liability

393,000


2,995,000


533,000


4,675,986

Other income (expense), net

151,506


2,753,542


48,166


1,261,830

Net loss

$ (3,763,976)


$ (3,341,397)


$ (6,537,017)


$ (10,329,722)

Net loss per common share, basic and diluted

$ (0.31)


$ (0.51)


$ (0.55)


$ (1.73)

Basic and diluted weighted average common shares outstanding

12,070,548


6,594,530


11,965,306


5,987,376









(Reflects 1-for-10 reverse stock split effective June 7, 2013)

 

SOURCE Echo Therapeutics, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The Internet of Everything (IoE) brings together people, process, data and things to make networked connections more relevant and valuable than ever before – transforming information into knowledge and knowledge into wisdom. IoE creates new capabilities, richer experiences, and unprecedented opportunities to improve business and government operations, decision making and mission support capabilities. In his session at @ThingsExpo, Gary Hall, Chief Technology Officer, Federal Defense at Cisco S...
The explosion of connected devices / sensors is creating an ever-expanding set of new and valuable data. In parallel the emerging capability of Big Data technologies to store, access, analyze, and react to this data is producing changes in business models under the umbrella of the Internet of Things (IoT). In particular within the Insurance industry, IoT appears positioned to enable deep changes by altering relationships between insurers, distributors, and the insured. In his session at @Things...
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, it is now feasible to create a rich desktop and tuned mobile experience with a single codebase, without compromising performance or usability.
SYS-CON Events announced today that Vitria Technology, Inc. will exhibit at SYS-CON’s @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Vitria will showcase the company’s new IoT Analytics Platform through live demonstrations at booth #330. Vitria’s IoT Analytics Platform, fully integrated and powered by an operational intelligence engine, enables customers to rapidly build and operationalize advanced analytics to deliver timely business outcomes ...
SYS-CON Events announced today that GENBAND, a leading developer of real time communications software solutions, has been named “Silver Sponsor” of SYS-CON's WebRTC Summit, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. The GENBAND team will be on hand to demonstrate their newest product, Kandy. Kandy is a communications Platform-as-a-Service (PaaS) that enables companies to seamlessly integrate more human communications into their Web and mobile applicatio...
VictorOps is making on-call suck less with the only collaborative alert management platform on the market. With easy on-call scheduling management, a real-time incident timeline that gives you contextual relevance around your alerts and powerful reporting features that make post-mortems more effective, VictorOps helps your IT/DevOps team solve problems faster.
The Internet of Things (IoT) is causing data centers to become radically decentralized and atomized within a new paradigm known as “fog computing.” To support IoT applications, such as connected cars and smart grids, data centers' core functions will be decentralized out to the network's edges and endpoints (aka “fogs”). As this trend takes hold, Big Data analytics platforms will focus on high-volume log analysis (aka “logs”) and rely heavily on cognitive-computing algorithms (aka “cogs”) to mak...
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, will discuss why containers should be paired with new architectural practices such as microservices ra...
Companies today struggle to manage the types and volume of data their customers and employees generate and use every day. With billions of requests daily, operational consistency can be elusive. In his session at Big Data Expo, Dave McCrory, CTO at Basho Technologies, will explore how a distributed systems solution, such as NoSQL, can give organizations the consistency and availability necessary to succeed with on-demand data, offering high availability at massive scale.
The speed of software changes in growing and large scale rapid-paced DevOps environments presents a challenge for continuous testing. Many organizations struggle to get this right. Practices that work for small scale continuous testing may not be sufficient as the requirements grow. In his session at DevOps Summit, Marc Hornbeek, Sr. Solutions Architect of DevOps continuous test solutions at Spirent Communications, will explain the best practices of continuous testing at high scale, which is r...
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, shared some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, de...
The industrial software market has treated data with the mentality of “collect everything now, worry about how to use it later.” We now find ourselves buried in data, with the pervasive connectivity of the (Industrial) Internet of Things only piling on more numbers. There’s too much data and not enough information. In his session at @ThingsExpo, Bob Gates, Global Marketing Director, GE’s Intelligent Platforms business, to discuss how realizing the power of IoT, software developers are now focu...
SYS-CON Media announced that IBM, which offers the world’s deepest portfolio of technologies and expertise that are transforming the future of work, has launched ad campaigns on SYS-CON’s numerous online magazines such as Cloud Computing Journal, Virtualization Journal, SOA World Magazine, and IoT Journal. IBM’s campaigns focus on vendors in the technology marketplace, the future of testing, Big Data and analytics, and mobile platforms.
Security can create serious friction for DevOps processes. We've come up with an approach to alleviate the friction and provide security value to DevOps teams. In her session at DevOps Summit, Shannon Lietz, Senior Manager of DevSecOps at Intuit, will discuss how DevSecOps got started and how it has evolved. Shannon Lietz has over two decades of experience pursuing next generation security solutions. She is currently the DevSecOps Leader for Intuit where she is responsible for setting and driv...
The explosion of connected devices / sensors is creating an ever-expanding set of new and valuable data. In parallel the emerging capability of Big Data technologies to store, access, analyze, and react to this data is producing changes in business models under the umbrella of the Internet of Things (IoT). In particular within the Insurance industry, IoT appears positioned to enable deep changes by altering relationships between insurers, distributors, and the insured. In his session at @Things...